Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Moderna (MRNA) and NewAmsterdam Pharma Company (NAMS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), Moderna (MRNA – Research Report) and NewAmsterdam Pharma Company (NAMS – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alnylam Pharma (ALNY)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, with a price target of $510.00. The company’s shares closed last Wednesday at $332.79.
According to TipRanks.com, Trucchio is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $455.84 average price target, representing a 38.6% upside. In a report issued on February 14, TipRanks – Google also upgraded the stock to Buy with a $349.00 price target.
See the top stocks recommended by analysts >>
Moderna (MRNA)
In a report released today, Myles Minter from William Blair maintained a Hold rating on Moderna. The company’s shares closed last Wednesday at $46.49, close to its 52-week low of $29.25.
According to TipRanks.com, Minter is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Moderna with a $34.13 average price target, a -26.9% downside from current levels. In a report issued on February 3, TD Cowen also maintained a Hold rating on the stock with a $40.00 price target.
NewAmsterdam Pharma Company (NAMS)
William Blair analyst Matt Phipps reiterated a Buy rating on NewAmsterdam Pharma Company today. The company’s shares closed last Wednesday at $36.98.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
Currently, the analyst consensus on NewAmsterdam Pharma Company is a Strong Buy with an average price target of $47.67, a 35.1% upside from current levels. In a report issued on February 6, Stifel Nicolaus also maintained a Buy rating on the stock with a $50.00 price target.
